Related Experiment Video

Updated: Jul 1, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

K S M Smalley1, M Xiao, J Villanueva

  • 1The Wistar Institute, Philadelphia, PA, USA. k.smalley@mac.com

Oncogene
|September 17, 2008
PubMed

Insights

Melanoma with specific BRAF mutations (G469E/D594G) resist MEK inhibitors but respond to CRAF inhibition. These BRAF mutants rely on CRAF for survival, offering a new therapeutic target for melanoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • BRAF mutations are common drivers in melanoma.
  • The V600E mutation is the most frequent BRAF alteration, conferring sensitivity to MEK inhibitors.
  • Non-V600E BRAF mutations represent a subset of melanoma with distinct signaling dependencies.

Purpose of the Study:

  • To investigate the therapeutic vulnerabilities of melanoma harboring non-V600E BRAF mutations.
  • To elucidate the signaling pathways utilized by these resistant melanoma subtypes.
  • To evaluate the efficacy of CRAF inhibition in BRAF-mutated melanoma models.

Main Methods:

  • Characterization of melanoma cell lines with G469E and D594G BRAF mutations.
  • Assessment of signaling pathway activation, including phospho-ERK (pERK) and phospho-MEK (pMEK).
  • Treatment with MEK and CRAF inhibitors (sorafenib), followed by apoptosis assays and western blotting.
  • CRAF knockdown studies using lentiviral shRNA.
  • Xenograft studies to evaluate in vivo tumor growth inhibition.

Main Results:

  • Melanoma lines with G469E/D594G BRAF mutations exhibited constitutive pERK and low pMEK, conferring resistance to MEK inhibition.
  • These cell lines underwent apoptosis upon sorafenib (CRAF inhibitor) treatment, unlike BRAF-V600E lines.
  • Signaling analysis revealed that low-activity BRAF mutants signal through CRAF, which directly regulates apoptosis.
  • Sorafenib reduced BAD phosphorylation and Bcl-2 expression in G469E/D594G lines, and CRAF knockdown induced apoptosis.
  • Sorafenib demonstrated greater potency in reducing tumor growth in xenografts with D594G mutations compared to V600E mutations.

Conclusions:

  • Melanomas with low-activity BRAF mutations (G469E/D594G) are dependent on CRAF-mediated survival signaling.
  • CRAF inhibition represents a promising therapeutic strategy for this subset of melanoma.
  • Understanding BRAF mutation status is crucial for selecting effective targeted therapies in melanoma.

More Related Videos

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...